Carriageway L P

Carriageway L P was paid $7.46M by Medicaid between Jan 2018 and May 2024, across 73 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 10.0% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Ohio

Rank by total paid#20 of 116

Median peer was paid$313K

This provider vs. median24×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	790,055	$5.35M
2019	69,080	$531K
2020	45,788	$512K
2021	29,202	$774K
2022	19,614	$288K
2023	1,453	$4K
2024incomplete	35	$72.00

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	10.0%	14,011	4,165	$746K
80346		6.9%	37,470	20,854	$517K
80361		6.0%	37,437	21,005	$448K
80363		4.9%	31,464	18,332	$369K
83992		4.3%	34,137	19,341	$317K
80321		4.1%	36,551	20,349	$305K
80348		3.3%	37,793	21,191	$249K
80349		3.3%	37,416	20,847	$247K
80365		3.3%	37,437	20,929	$247K
80353		3.3%	37,100	20,737	$244K
80356		3.3%	37,038	20,690	$244K
80359		3.2%	36,832	20,566	$242K

61 more codes

80325		3.0%	34,175	$222K
80345		2.8%	32,002	$212K
80354		2.8%	33,484	$212K
80373		2.7%	30,910	$201K
80372		2.7%	30,587	$199K
80358		2.6%	29,773	$194K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.6%	11,456	$192K
80333		2.4%	28,084	$182K
80336		2.4%	28,062	$182K
80338		2.4%	27,976	$182K
84311		2.2%	37,206	$167K
80355		2.0%	21,660	$152K
82570		1.7%	37,292	$127K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.6%	1,376	$120K
80366		1.6%	17,143	$119K
83986		1.2%	37,481	$89K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	1,716	$70K
80360		<1%	10,509	$64K
80323		<1%	11,598	$61K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	666	$45K
80368		<1%	6,590	$39K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	1,013	$37K
80362		<1%	2,501	$33K
80324		<1%	3,111	$25K
80370		<1%	4,597	$24K
80369		<1%	2,250	$17K
80053	Comprehensive metabolic panel	<1%	4,935	$13K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,332	$12K
80061	Lipid panel	<1%	1,880	$10K
84443	Thyroid stimulating hormone (TSH)	<1%	1,686	$9K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,724	$8K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	2,146	$8K
80367		<1%	852	$8K
81025		<1%	1,014	$6K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	11,303	$6K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	323	$5K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,663	$5K
36415	Collection of venous blood by venipuncture	<1%	4,619	$4K
80048	Basic metabolic panel (calcium, ionized)	<1%	3,175	$4K
85027		<1%	3,174	$4K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	67	$4K
80364		<1%	108	$1K
85610		<1%	1,591	$1K
82607		<1%	303	$1K
80164		<1%	170	$831.30
80339		<1%	4,418	$786.27
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	7,537	$702.05
82728		<1%	49	$491.78
81000		<1%	555	$394.10
80357		<1%	60	$365.05
80320		<1%	34	$339.78
80371		<1%	45	$309.87
83540		<1%	128	$231.49
80342		<1%	39	$194.20
84436		<1%	122	$154.10
82140		<1%	37	$127.20
84479		<1%	98	$110.23
84466		<1%	55	$104.50
80050	General health panel	<1%	36	$84.98
80076		<1%	30	$58.24
82043		<1%	15	$52.08

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZOCCO, KRISTEN (VICE PRESIDENT)